Aktis Oncology Inc.
AKTS | NASDAQ
$14.23
-$1.70 (-10.67%)
Nov 2, 2026, 11:25 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 | Q1 2025 Mar 31, 2025 | Q4 2024 Dec 31, 2024 |
|---|---|---|---|---|---|---|---|
Revenue | 10.06M | 8.28M | 6.5M | 5.56M | 3.98M | 2.38M | 933K |
Cost of Revenue | 1.53M | 652K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 8.53M | 7.63M | 6.5M | 5.56M | 3.98M | 2.38M | 933K |
Operating Income | -87.18M | -79.25M | -74.68M | -72.94M | -54.74M | -33.78M | -15.64M |
Interest Income | 14.08M | 12.22M | 11.01M | 12.34M | 9.66M | 6.75M | 3.58M |
Pretax Income | -73.14M | -67.07M | -63.73M | -60.65M | -45.12M | -27.04M | -12.06M |
Net Income | -73.14M | -67.07M | -63.73M | -60.65M | -45.12M | -27.04M | -12.06M |
Selling & General & Admin | 16.94M | 14.5M | 12.6M | 14.03M | 10.97M | 7.29M | 3.94M |
Research & Development | 78.28M | 71.62M | 67.45M | 63.56M | 47.1M | 28.47M | 12.61M |
Other Expenses | 496K | 751K | 1.13M | 911K | 657K | 402K | 21K |
Operating Expenses | 95.71M | 86.87M | 81.18M | 78.5M | 58.72M | 36.16M | 16.57M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 97.24M | 87.52M | 81.18M | 78.5M | 58.72M | 36.16M | 16.57M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 55.32M | 55.28M | 53.4M | n/a | 52.52M | 34.86M | 52.52M |
Shares Outstanding (Diluted) | 55.32M | 55.28M | 53.4M | n/a | 52.52M | 34.86M | 52.52M |
EPS (Basic) | -1.05 | -0.95 | -1.05 | -1 | -1 | -0.66 | -0.23 |
EPS (Diluted) | -1.05 | -0.95 | -1.05 | -1 | -1 | -0.66 | -0.23 |
EBITDA | -77.74M | -70.13M | -70.12M | -67.29M | -49.69M | -29.27M | -11.62M |
EBIT | -80.57M | -72.63M | -72.45M | -69.37M | -51.16M | -30.2M | -12.06M |
Depreciation & Amortization | 2.82M | 2.5M | 2.33M | 2.08M | 1.48M | 925K | 441K |
Add to Watchlist
Select watchlists to add or remove AKTS